Relating To Harm Reduction.
SB1433 revises Hawaii’s sterile needle and syringe exchange program, renaming and broadening it in practice from a strict one-to-one exchange model to a needs-based distribution system. The bill is framed as a harm-reduction measure intended to reduce HIV, hepatitis B, hepatitis C, and other bloodborne infections by allowing participants to receive sterile syringes in quantities sufficient to avoid sharing or reuse. It also expands the program’s scope to include additional injection-related supplies, called “authorized objects,” and updates program definitions to reflect current public health terminology and practice.
The bill also changes who may participate and what services the program may provide. It removes the requirement that the program exclude non-injection drug users, allowing them to receive non-syringe services such as referrals, counseling, and other harm-reduction support when resources are available. The Department of Health must continue to provide education, treatment referrals, and annual reporting on program use, participant demographics, disease transmission impacts, and cost-effectiveness. The bill keeps the program under oversight and preserves reporting obligations to evaluate whether it is reducing risk and improving access to services.
A major legal effect of the bill is to revise criminal-liability protections for participants and program staff. It clarifies that possession or delivery of syringes, needles, and authorized objects by program staff or participants during program visits is not an offense under the state’s paraphernalia law, and it adds a limited immunity for possession or delivery of used syringes containing drug residue for participants within two months of their last program visit. It also limits these protections to program-related conduct and expressly preserves prosecution for conduct outside the program’s scope. The bill further provides that law enforcement officers acting in good faith are not civilly liable for arrests or charges later found to fall within the exemption.
Overall, the bill appears to have been received favorably in committee, with unanimous or near-unanimous votes at several stages and amendments adopted along the way. The discussion reflected a public-health-oriented consensus that needs-based distribution is more effective than one-to-one exchange and that broader liability protections may improve safe disposal and participation. The main points of contention are implicit in the policy changes themselves: expanding access to non-injection drug users, extending immunity for residue on used syringes, and moving away from a stricter exchange limit may raise concerns about scope, enforcement, and whether the program could be used beyond its intended harm-reduction purpose. However, the recorded votes suggest those concerns did not prevent advancement of the bill.
The bill amends Hawaii Revised Statutes chapter 325 governing the sterile needle and syringe exchange program. It replaces the one-to-one syringe exchange requirement with a needs-based distribution model, adds definitions for authorized objects, needs-based distribution, program staff, residue, and syringe exchange participant, and revises program operation, reporting, and liability provisions. It also narrows and clarifies criminal-paraphernalia and drug-possession exemptions for program-related conduct while preserving general controlled-substance laws outside the program’s protections.
The overall sentiment appears supportive and public-health focused. The bill advanced through Senate Health and Human Services, Senate Judiciary, and conference committees with favorable votes and amendments, indicating broad agreement on the need to modernize the program. The framing in the bill text emphasizes evidence-based harm reduction, disease prevention, and cost savings, and the vote history suggests those arguments were persuasive to most legislators.
The main areas of potential contention are the shift from a one-to-one exchange to needs-based distribution, the inclusion of non-injection drug users in program services, and the expansion of legal protections for possession of residue and authorized objects. Critics could view these changes as broadening the program beyond syringe exchange into a wider harm-reduction model and as complicating enforcement of drug and paraphernalia laws. Supporters, by contrast, argue these changes are necessary to reduce infection risk, improve disposal, and align state law with CDC guidance and federal model recommendations.